Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer

Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer

Abstract Background Mammary cancer has a high incidence in canines and is an excellent model of spontaneous carcinogenesis. Molecular iodine (I2) exerts antineoplastic effects on different cancer cells activating re-differentiation pathways. In co-administration with anthracyclines, I2 impairs chemo...

Full description

Bibliographic Details
Main Authors: Xóchitl Zambrano-Estrada, Brianda Landaverde-Quiroz, Andrés A. Dueñas-Bocanegra, Marco A. De Paz-Campos, Gerardo Hernández-Alberto, Benjamín Solorio-Perusquia, Manuel Trejo-Mandujano, Laura Pérez-Guerrero, Evangelina Delgado-González, Brenda Anguiano, Carmen Aceves
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Veterinary Research
Subjects:
Canine mammary cancer
Molecular iodine
Neoadjuvant chemotherapy
Doxorubicin
Animal welfare
Online Access:http://link.springer.com/article/10.1186/s12917-018-1411-6

Internet

http://link.springer.com/article/10.1186/s12917-018-1411-6

Similar Items